• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/11/21 3:59:00 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPPI alert in real time by email
    SC 13G 1 Spectrum_Pharmaceuticals_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING SPECTRUM PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 84763A108 (CUSIP NUMBER) 12/31/2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO: 84763A108 13G PAGE 2 OF 7 PAGES 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 10,018,483 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 10,586,684 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,586,684 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.26% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 84763A108 13G PAGE 3 OF 7 PAGES 1. NAME OF REPORTING PERSON: SSGA FUNDS MANAGEMENT, INC. I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-3555193 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 7,918,855 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 7,964,234 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,964,234 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.46% 12. TYPE OF REPORTING PERSON IA CUSIP NO: 84763A108 13G PAGE 4 OF 7 PAGES ITEM 1. (A) NAME OF ISSUER SPECTRUM PHARMACEUTICALS INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 11500 SOUTH EASTERN AVENUE SUITE 240 HENDERSON NV 89052 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION SSGA FUNDS MANAGEMENT, INC (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IN NONE, RESIDENCE STATE STREET FINANCIAL CENTER ONE LINCOLN STREET BOSTON, MA 02111 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 84763A108 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO: 84763A108 13G PAGE 5 OF 7 PAGES ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMEBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO: 84763A108 13G PAGE 6 OF 7 PAGES ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. CHRISTOPHER MICAH BAKER CHIEF COMPLIANCE OFFICER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS LIMITED (UK) IA STATE STREET GLOBAL ADVISORS, AUSTRALIA LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION. CUSIP NO: 84763A108 13G PAGE 7 OF 7 PAGES JOINT FILING AGREEMENT IN ACCORDANCE WITH RULE 13D-1(K)(1) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE EXCHANGE ACT), EACH UNDERSIGNED ENTITY (EACH A COMPANY) HEREBY AGREES TO ANY AND ALL JOINT FILINGS REQUIRED TO BE MADE ON THE COMPANY`S BEHALF ON SCHEDULE 13G (INCLUDING AMENDMENTS THERETO) UNDER THE EXCHANGE ACT, WITH RESPECT TO SECURITIES WHICH MAY BE DEEMED TO BE BENEFICIALLY OWNED BY THE COMPANY UNDER THE EXCHANGE ACT, AND THAT THIS AGREEMENT BE INCLUDED AS AN EXHIBIT TO ANY SUCH JOINT FILING. THIS AGREEMENT MAY BE EXECUTED IN ANY NUMBER OF COUNTERPARTS ALL OF WHICH TAKEN TOGETHER SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT. IN WITNESS WHEREOF, EACH COMPANY HEREBY EXECUTES THIS AGREEMENT EFFECTIVE AS OF THE DATE SET FORTH BELOW. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. CHRISTOPHER MICAH BAKER CHIEF COMPLIANCE OFFICER
    Get the next $SPPI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPPI

    DatePrice TargetRatingAnalyst
    4/26/2023Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $SPPI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Spectrum Pharmaceuticals Inc.

      15-12G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

      11/9/23 5:00:17 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Spectrum Pharmaceuticals Inc.

      EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

      9/28/23 12:15:18 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Spectrum Pharmaceuticals Inc.

      EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

      9/28/23 12:15:20 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spectrum Pharma downgraded by JMP Securities

      JMP Securities downgraded Spectrum Pharma from Mkt Outperform to Mkt Perform

      4/26/23 6:26:55 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

      Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business

      7/31/23 7:27:24 PM ET
      $ASRT
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

      Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and

      7/27/23 4:01:00 PM ET
      $ASRT
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR" Proposed Transaction with Assertio Holdings, Inc.

      Recommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger ("Merger Agreement", and such proposal, the "Merger Proposal") at the upcoming special meeting of stockholders (the "Special Meeting") on July 27, 2023. Under the terms of the M

      7/20/23 7:00:00 AM ET
      $ASRT
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bradrick Brittany returned 27,380 shares to the company, closing all direct ownership in the company

      4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

      8/1/23 5:22:18 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Mcgahan Keith M returned 618,312 shares to the company, closing all direct ownership in the company

      4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

      8/1/23 5:20:08 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lim Juhyun returned 29,759 shares to the company, closing all direct ownership in the company

      4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

      8/1/23 5:17:13 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Leadership Updates

    Live Leadership Updates

    See more
    • Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

      Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business

      7/31/23 7:27:24 PM ET
      $ASRT
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

      Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role. "We are thrilled to have Ms. Brennan join Spectrum's senior leadership team as we progress our two late-stage assets toward commercialization," stated Tom Riga, CEO of Spectrum Pharmaceuticals. "Nora has been a strong board member and her experience as the audit committee chair will serve her well i

      5/11/22 7:00:00 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

      Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience. "It's my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum's evolution," stated William Ashton, Chairman of the Board of Spectrum Pharmaceuticals. "As a seasoned executive in M&A and the life sciences sector, Brittany's experience and leadership will make an immediate impact on our board." "I am looking forward to joining Spectrum's Board at a

      5/5/22 7:00:00 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Spectrum Pharmaceuticals Inc. (Amendment)

      SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

      2/14/23 1:30:26 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spectrum Pharmaceuticals Inc.

      SC 13G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

      2/10/22 4:05:14 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Spectrum Pharmaceuticals Inc.

      SC 13D - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

      2/1/22 4:00:34 PM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPPI
    Financials

    Live finance-specific insights

    See more
    • Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

      Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres

      4/25/23 6:00:00 AM ET
      $ASRT
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

      -- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation

      3/22/23 8:00:00 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

      Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web

      3/17/23 7:00:00 AM ET
      $SPPI
      Biotechnology: Pharmaceutical Preparations
      Health Care